Aclaris Therapeutics (ACRS) AI Stock Analysis

• Market Cap: $193.91M
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -47.56%
• EPS Growth: -65.54%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.13
• Shares Outstanding: 108,332,214
• 10 Day Avg. Volume: 936,064
• 30 Day Avg. Volume: 1,235,665
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 4.56
• Enterprise Value/Gross Profit: 18.88
• Enterprise Value/Ebitda: -1.36
• 1Y Price Target: $7.92
• Price Target Upside: 352.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 55 Neutral
• Price Target: $1.50 ▼(-14.29% Downside)

Aclaris Therapeutics' overall stock score reflects its financial challenges, with negative profitability and cash flow issues being significant concerns. However, positive technical indicators and promising corporate events, such as successful clinical trials and strategic growth plans, provide a more optimistic outlook. The valuation remains a concern due to the negative P/E ratio, but the company's strategic initiatives could improve future performance.

Positive Factors

Clinical Trials

Aclaris Therapeutics reported strong proof-of-concept results for its ITK/JAK3 inhibitor in atopic dermatitis with high tolerability and rapid responses.

Product Development

ACRS is developing a pair of recently in-licensed antibody assets, indicating continued pipeline progress and potential future growth.

Safety Profile

The favorable safety profile of ATI-2138, if sustained, is expected to provide a key competitive advantage against approved JAK inhibitors.

Negative Factors

Conflicts of Interest

Investors should be aware of potential conflicts of interest as Wedbush Securities seeks to do business with companies covered in its research reports.

Study Design and Sample Size

Compared to the atopic dermatitis clinical landscape, '2138's treatment effect is competitive, though the study's design and sample size are noted.

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Aclaris Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding through various streams, including upfront payments and milestone payments from partnerships with larger pharmaceutical companies, as well as royalties on product sales. Additionally, Aclaris may also generate revenue from licensing agreements that allow other companies to develop or market its drug candidates. The company actively seeks collaborations to enhance its research capabilities and expand its market reach, which contributes to its overall earnings.

Aclaris Therapeutics Financial Statement Overview

Summary

Aclaris Therapeutics faces significant challenges in achieving profitability and positive cash flow, despite a strong balance sheet with no debt and substantial cash reserves. Revenue growth is inconsistent, and ongoing losses suggest a need for strategic changes to improve operational efficiency. The company's ability to maintain financial health is contingent on continued access to external financing and cost management improvements.

Income Statement

Aclaris Therapeutics has experienced fluctuating revenue growth, with a decline from 2023 to 2024. The company struggles with profitability, indicated by substantial negative EBIT, EBITDA, and net income margins. Gross profit margin is relatively high, suggesting effective cost management at the gross level, but significant operating losses highlight challenges in controlling other expenses.

Balance Sheet

The balance sheet displays a strong equity position with zero debt in 2024, leading to a healthy equity ratio. However, consistent losses have eroded equity over time. The company maintains significant cash reserves which provide a buffer against operational losses, but the lack of profitability poses a long-term risk.

Cash Flow

Cash flow analysis reveals negative operating cash flow, indicating a reliance on external financing to sustain operations. Free cash flow remains negative, although there is a slight improvement in cash flow stability compared to previous years. The company is capable of raising capital, as evidenced by positive financing cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.79M	18.72M	31.25M	29.75M	6.76M	6.48M
Gross Profit	4.06M	15.93M	13.17M	17.79M	2.05M	1.35M
EBITDA	-56.29M	-51.72M	-87.98M	-84.36M	-64.46M	-50.01M
Net Income	-134.65M	-132.06M	-88.48M	-86.91M	-90.86M	-51.15M
Balance Sheet
Total Assets	189.15M	220.33M	197.41M	254.60M	251.21M	70.78M
Cash, Cash Equivalents and Short-Term Investments	99.81M	113.59M	119.11M	217.57M	191.41M	54.13M
Total Debt	2.37M	2.60M	3.50M	2.25M	2.89M	14.15M
Total Liabilities	57.41M	64.77M	40.23M	56.98M	53.87M	33.13M
Stockholders Equity	131.74M	155.55M	157.18M	197.62M	197.34M	37.65M
Cash Flow
Free Cash Flow	-45.86M	-20.20M	-79.63M	-68.17M	-52.44M	-39.09M
Operating Cash Flow	-9.99M	-20.07M	-78.33M	-67.57M	-52.13M	-38.63M
Investing Cash Flow	-61.76M	-69.77M	46.22M	12.63M	-167.63M	6.39M
Financing Cash Flow	74.32M	74.54M	26.71M	72.87M	225.05M	18.37M

Aclaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 1.75 is above the 20-day moving average (MA) of 1.66, above the 50-day MA of 1.58, and below the 200-day MA of 2.00, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 58.84 is Neutral, neither overbought nor oversold. The STOCH value of 62.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.

Aclaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XGN	61 Neutral	$212.34M	―	-87.94%	―	3.89%	7.92%
ACRS	55 Neutral	$193.91M	―	-101.41%	―	-47.56%	-65.54%
MDXH	53 Neutral	$143.54M	―	-1552.23%	―	22.56%	41.62%
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%
STIM	45 Neutral	$222.84M	―	-207.57%	―	54.17%	-2.43%
NOTV	43 Neutral	$57.72M	―	-48.46%	―	0.85%	29.83%
SERA	42 Neutral	$85.64M	―	-44.24%	―	0.93%	13.99%

Aclaris Therapeutics Corporate Events

Aclaris Therapeutics Announces Positive Phase 2a Trial Results

On July 29, 2025, Aclaris Therapeutics announced the top-line results of their Phase 2a clinical trial for ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, in subjects with moderate to severe atopic dermatitis. The trial showed that ATI-2138 was well tolerated with no severe adverse events, and demonstrated significant efficacy, with a mean improvement in Eczema Area and Severity Score (EASI) of 77% over 12 weeks, excluding outliers. This development could enhance Aclaris’ positioning in the treatment of immuno-inflammatory diseases, offering a promising therapeutic option for patients and potentially impacting future market strategies.

Aclaris Therapeutics Highlights Clinical Pipeline and Outlook

On June 30, 2025, Aclaris Therapeutics updated its corporate overview presentation, highlighting its robust clinical pipeline and financial outlook. The company is advancing several drug candidates, including bosakitug, ATI-052, and ATI-2138, with ongoing clinical trials and expected data releases in 2025. Aclaris anticipates its current cash reserves will fund operations through the first half of 2028, with potential for additional non-dilutive financing. The announcement underscores Aclaris’ strategic positioning for growth and its commitment to developing innovative therapies for immuno-inflammatory diseases.

Aclaris Therapeutics Approves 2025 Equity Incentive Plan

On June 5, 2025, Aclaris Therapeutics‘ stockholders approved the 2025 Equity Incentive Plan, succeeding the 2015 plan, during their annual meeting. Additionally, they approved an amendment to increase the authorized common stock shares from 200 million to 400 million, reflecting strategic growth intentions. The meeting also resulted in the election of three board directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the accounting firm for 2025.